306 related articles for article (PubMed ID: 29556234)
21. Long Pentraxin-3 Modulates the Angiogenic Activity of Fibroblast Growth Factor-2.
Presta M; Foglio E; Churruca Schuind A; Ronca R
Front Immunol; 2018; 9():2327. PubMed ID: 30349543
[TBL] [Abstract][Full Text] [Related]
22. Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3.
Camozzi M; Rusnati M; Bugatti A; Bottazzi B; Mantovani A; Bastone A; Inforzato A; Vincenti S; Bracci L; Mastroianni D; Presta M
J Biol Chem; 2006 Aug; 281(32):22605-13. PubMed ID: 16769728
[TBL] [Abstract][Full Text] [Related]
23. Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells.
Ronca R; Di Salle E; Giacomini A; Leali D; Alessi P; Coltrini D; Ravelli C; Matarazzo S; Ribatti D; Vermi W; Presta M
Mol Cancer Ther; 2013 Dec; 12(12):2760-71. PubMed ID: 24130051
[TBL] [Abstract][Full Text] [Related]
24. The Role of PTX3 in Mineralization Processes and Aging-Related Bone Diseases.
Tarantino U; Greggi C; Cariati I; Visconti VV; Gasparini M; Cateni M; Gasbarra E; Botta A; Salustri A; Scimeca M
Front Immunol; 2020; 11():622772. PubMed ID: 33584725
[TBL] [Abstract][Full Text] [Related]
25. Pentraxin 3 accelerates lung injury in high tidal volume ventilation in mice.
Real JM; Spilborghs GM; Morato-Marques M; de Moura RP; Negri EM; Camargo AA; Deheinzelin D; Dias AA
Mol Immunol; 2012 May; 51(1):82-90. PubMed ID: 22425349
[TBL] [Abstract][Full Text] [Related]
26. Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model?
Alzahrani MM; Rauch F; Hamdy RC
Clin Orthop Relat Res; 2016 May; 474(5):1294-302. PubMed ID: 26608966
[TBL] [Abstract][Full Text] [Related]
27. Pentraxin-3 modulates lipopolysaccharide-induced inflammatory response and attenuates liver injury.
Perea L; Coll M; Sanjurjo L; Blaya D; Taghdouini AE; Rodrigo-Torres D; Altamirano J; Graupera I; Aguilar-Bravo B; Llopis M; Vallverdú J; Caballeria J; van Grunsven LA; Sarrias MR; Ginès P; Sancho-Bru P
Hepatology; 2017 Sep; 66(3):953-968. PubMed ID: 28422322
[TBL] [Abstract][Full Text] [Related]
28. Impairment of PTX3 expression in osteoblasts: a key element for osteoporosis.
Scimeca M; Salustri A; Bonanno E; Nardozi D; Rao C; Piccirilli E; Feola M; Tancredi V; Rinaldi A; Iolascon G; Orlandi A; Gasbarra E; Maffulli N; Brandi ML; Tarantino U
Cell Death Dis; 2017 Oct; 8(10):e3125. PubMed ID: 29022895
[TBL] [Abstract][Full Text] [Related]
29. Micro-computed tomography assessment of the progression of fracture healing in mice.
O'Neill KR; Stutz CM; Mignemi NA; Burns MC; Murry MR; Nyman JS; Schoenecker JG
Bone; 2012 Jun; 50(6):1357-67. PubMed ID: 22453081
[TBL] [Abstract][Full Text] [Related]
30. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
31. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps.
Jaillon S; Peri G; Delneste Y; Frémaux I; Doni A; Moalli F; Garlanda C; Romani L; Gascan H; Bellocchio S; Bozza S; Cassatella MA; Jeannin P; Mantovani A
J Exp Med; 2007 Apr; 204(4):793-804. PubMed ID: 17389238
[TBL] [Abstract][Full Text] [Related]
32. Inducible expression of the long pentraxin PTX3 in the central nervous system.
Polentarutti N; Bottazzi B; Di Santo E; Blasi E; Agnello D; Ghezzi P; Introna M; Bartfai T; Richards G; Mantovani A
J Neuroimmunol; 2000 Jul; 106(1-2):87-94. PubMed ID: 10814786
[TBL] [Abstract][Full Text] [Related]
33. Increased fracture callus mineralization and strength in cathepsin K knockout mice.
Gentile MA; Soung do Y; Horrell C; Samadfam R; Drissi H; Duong LT
Bone; 2014 Sep; 66():72-81. PubMed ID: 24928497
[TBL] [Abstract][Full Text] [Related]
34. [Advances on pentraxin 3 in osteoporosis and fracture healing].
Lu JJ; Sun Y; Zhang X; Wang QQ; Xiang ZY; Ling YQ; Tong PJ; Xu TT
Zhongguo Gu Shang; 2023 Apr; 36(4):393-8. PubMed ID: 37087632
[TBL] [Abstract][Full Text] [Related]
35. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide.
Leali D; Bianchi R; Bugatti A; Nicoli S; Mitola S; Ragona L; Tomaselli S; Gallo G; Catello S; Rivieccio V; Zetta L; Presta M
J Cell Mol Med; 2010 Aug; 14(8):2109-21. PubMed ID: 19627396
[TBL] [Abstract][Full Text] [Related]
36. Validation of the modified radiographic union score for tibia fractures (mRUST) in murine femoral fractures.
Alentado VJ; Knox AM; Staut CA; McGuire AC; Chitwood JR; Mostardo SL; Shaikh MZ; Blosser RJ; Dadwal UC; Chu TG; Collier CD; Li J; Liu Z; Kacena MA; Natoli RM
Front Endocrinol (Lausanne); 2022; 13():911058. PubMed ID: 35992150
[TBL] [Abstract][Full Text] [Related]
37. The Long Pentraxin PTX3 as a Link Between Innate Immunity, Tissue Remodeling, and Cancer.
Doni A; Stravalaci M; Inforzato A; Magrini E; Mantovani A; Garlanda C; Bottazzi B
Front Immunol; 2019; 10():712. PubMed ID: 31019517
[TBL] [Abstract][Full Text] [Related]
38. Pentraxin-3 and endothelial dysfunction.
Zlibut A; Bocsan IC; Agoston-Coldea L
Adv Clin Chem; 2019; 91():163-179. PubMed ID: 31331488
[TBL] [Abstract][Full Text] [Related]
39. Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases.
Bonacina F; Baragetti A; Catapano AL; Norata GD
Mediators Inflamm; 2013; 2013():725102. PubMed ID: 23690668
[TBL] [Abstract][Full Text] [Related]
40. Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation.
Bonacina F; Barbieri SS; Cutuli L; Amadio P; Doni A; Sironi M; Tartari S; Mantovani A; Bottazzi B; Garlanda C; Tremoli E; Catapano AL; Norata GD
Biochim Biophys Acta; 2016 Jun; 1862(6):1182-90. PubMed ID: 26976330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
